KRAS and non-small cell lung carcinoma: Research on inhibitors targeting the KRAS G12C mutation has made remarkable progress, such as Sotorasib, can be used to treat non-small cell lung cancer patients carrying the KRAS G12C mutation (18).There is currently no corresponding drug on the market for the KRAS G12V mutation, but studies are ongoing.